Drugs / BHV-1400
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07054684 | Jul 2025 → Jul 2027 expected | IgA glomerulonephritis | Biohaven Therapeutics Ltd. | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07642050 | Jun 2026 → Sep 2028 expected | IgA glomerulonephritis | Biohaven Therapeutics Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BHV-1400 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07642050 ↗ |
| Route | Subcutaneous | “subcutaneously (SC)” NCT07054684 ↗ |